Log in

NASDAQ:BDSI - BioDelivery Sciences International Stock Price, Forecast & News

+0.02 (+0.57 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
Now: $3.53
50-Day Range
MA: $4.55
52-Week Range
Now: $3.53
Volume1.07 million shs
Average Volume1.41 million shs
Market Capitalization$340.15 million
P/E RatioN/A
Dividend YieldN/A
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. has a licensing and development agreement with Evonik Corporation and Meda AB. The company was founded in 1997 and is headquartered in Raleigh, North Carolina.
Read More
BioDelivery Sciences International logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BDSI



Sales & Book Value

Annual Sales$111.39 million
Cash Flow$0.19 per share
Book Value$0.78 per share


Net Income$-15,310,000.00


Market Cap$340.15 million
Next Earnings Date5/4/2020 (Estimated)

Receive BDSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BDSI and its competitors with MarketBeat's FREE daily newsletter.

BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions

How has BioDelivery Sciences International's stock been impacted by COVID-19 (Coronavirus)?

BioDelivery Sciences International's stock was trading at $3.96 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BDSI shares have decreased by 10.9% and is now trading at $3.53. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BioDelivery Sciences International?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioDelivery Sciences International.

When is BioDelivery Sciences International's next earnings date?

BioDelivery Sciences International is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for BioDelivery Sciences International.

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) issued its quarterly earnings data on Thursday, March, 12th. The specialty pharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.03. The specialty pharmaceutical company earned $31.60 million during the quarter, compared to analyst estimates of $30.10 million. BioDelivery Sciences International had a negative net margin of 13.74% and a positive return on equity of 13.41%. View BioDelivery Sciences International's earnings history.

What guidance has BioDelivery Sciences International issued on next quarter's earnings?

BioDelivery Sciences International issued an update on its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $110-110 million, compared to the consensus revenue estimate of $111 million.

What price target have analysts set for BDSI?

6 brokerages have issued twelve-month price objectives for BioDelivery Sciences International's shares. Their forecasts range from $8.00 to $9.00. On average, they expect BioDelivery Sciences International's share price to reach $8.50 in the next year. This suggests a possible upside of 140.8% from the stock's current price. View analysts' price targets for BioDelivery Sciences International.

What are Wall Street analysts saying about BioDelivery Sciences International stock?

Here are some recent quotes from research analysts about BioDelivery Sciences International stock:
  • 1. According to Zacks Investment Research, "BioDelivery has improved positioning in several managed care contracts, providing preferred access to Belbuca. The company’s efforts have brought 165 million patients under coverage with access to Belbuca so far in 2019, beginning with 7 million in 2018. The company’s efforts boosted the drug’s sales and the momentum is expected to continue in 2020. The acquisition of U.S. rights of Symproic strengthened the chronic pain portfolio. Shares have outperformed the industry in the past year. However, given the lackluster performance of Bunavail, BioDelivery has decided to reduce spending on the drug. The company’s portfolio and pipeline may face severe competition as these target a highly genericized and crowded market." (3/10/2020)
  • 2. Cantor Fitzgerald analysts commented, ". Post BDSI’s recent acquisition of U.S. commercial rights to Symproic, and equity raise, we are updating our model and reiterating our Overweight rating and 12-month price target of $8. BDSI has built a strong commercial team around Belbuca, and the acquisition leverages the company’s commercial strengths, and footprint, to grow its portfolio. We view the acquisition of Symproic as a positive as it diversifies the company’s revenue away from a single product, Belbuca, and can add a meaningful revenue contribution of $75MM + without the need for any significant increase in spending." (4/16/2019)

Has BioDelivery Sciences International been receiving favorable news coverage?

Press coverage about BDSI stock has been trending positive this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BioDelivery Sciences International earned a coverage optimism score of 2.4 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutBioDelivery Sciences International.

Are investors shorting BioDelivery Sciences International?

BioDelivery Sciences International saw a increase in short interest in February. As of February 28th, there was short interest totaling 3,300,000 shares, an increase of 9.3% from the February 13th total of 3,020,000 shares. Based on an average trading volume of 1,220,000 shares, the days-to-cover ratio is presently 2.7 days. Approximately 4.0% of the shares of the company are sold short. View BioDelivery Sciences International's Current Options Chain.

Who are some of BioDelivery Sciences International's key competitors?

What other stocks do shareholders of BioDelivery Sciences International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), Eldorado Gold (EGO), Synergy Pharmaceuticals (SGYP), NVIDIA (NVDA), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX), Horizon Therapeutics (HZNP), Exelixis (EXEL) and Novavax (NVAX).

Who are BioDelivery Sciences International's key executives?

BioDelivery Sciences International's management team includes the following people:
  • Mr. Herm Cukier, CEO & Director (Age 52)
  • Mr. Scott M. Plesha, Pres & Chief Commercial Officer (Age 54)
  • Mr. James Vollins J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 50)
  • Dr. Thomas B. Smith FAAFP, M.D., Chief Medical Officer (Age 58)
  • Mr. Ernest Robert De Paolantonio CPA, MBA, Exec. Officer (Age 66)

What is BioDelivery Sciences International's stock symbol?

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

Who are BioDelivery Sciences International's major shareholders?

BioDelivery Sciences International's stock is owned by many different retail and institutional investors. Top institutional shareholders include Emerald Mutual Fund Advisers Trust (2.23%), State Street Corp (2.09%), Nuveen Asset Management LLC (1.99%), Geode Capital Management LLC (1.26%), Renaissance Technologies LLC (1.24%) and Goldman Sachs Group Inc. (1.05%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Mary Theresa Coelho, Paolantonio Ernest Robert De, Scott M Plesha and Thomas B Smith. View institutional ownership trends for BioDelivery Sciences International.

Which major investors are selling BioDelivery Sciences International stock?

BDSI stock was sold by a variety of institutional investors in the last quarter, including Penn Capital Management Co. Inc., J. Goldman & Co LP, Mackay Shields LLC, Los Angeles Capital Management & Equity Research Inc., Oxford Asset Management LLP, PNC Financial Services Group Inc., New York State Common Retirement Fund, and California Public Employees Retirement System. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Mary Theresa Coelho, Scott M Plesha, and Thomas B Smith. View insider buying and selling activity for BioDelivery Sciences International.

Which major investors are buying BioDelivery Sciences International stock?

BDSI stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Marshall Wace LLP, EAM Investors LLC, Nuveen Asset Management LLC, Goldman Sachs Group Inc., Panagora Asset Management Inc., Assenagon Asset Management S.A., and State Street Corp. View insider buying and selling activity for BioDelivery Sciences International.

How do I buy shares of BioDelivery Sciences International?

Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioDelivery Sciences International's stock price today?

One share of BDSI stock can currently be purchased for approximately $3.53.

How big of a company is BioDelivery Sciences International?

BioDelivery Sciences International has a market capitalization of $340.15 million and generates $111.39 million in revenue each year. The specialty pharmaceutical company earns $-15,310,000.00 in net income (profit) each year or $0.10 on an earnings per share basis. BioDelivery Sciences International employs 164 workers across the globe. View additional information about BioDelivery Sciences International.

What is BioDelivery Sciences International's official website?

The official website for BioDelivery Sciences International is http://www.bdsi.com/.

How can I contact BioDelivery Sciences International?

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]

MarketBeat Community Rating for BioDelivery Sciences International (NASDAQ BDSI)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  532 (Vote Outperform)
Underperform Votes:  336 (Vote Underperform)
Total Votes:  868
MarketBeat's community ratings are surveys of what our community members think about BioDelivery Sciences International and other stocks. Vote "Outperform" if you believe BDSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel